CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Press Release

PRESS RELEASE

FY 2023-24

Novermber-23
30-Nov Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
10-Nov Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%
08-Nov Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations – India Business Units
October-23
31-Oct Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector
19-Oct Kedar Upadhye Appointed as New CFO of Biocon Biologics Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group
06-Oct Biocon Limited signs commercialization agreement with Juno Pharmaceuticals in Canada
September-23
18-Sep Biocon Board Appoints Peter Bains as Group CEO
07-Sep Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh
06-Sep Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule
01-Sep Biocon Limited announces the acquisition of a manufacturing facility of Eywa Pharma Inc.
August-23
10-Aug Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25% EBITDA at Rs 808 Cr, Up 69%; Core EBITDA at Rs 936 Cr, Up 42% Net Profit at Rs 101 Cr
10-Aug Biocon Foundation and Shakti Sustainable Energy Foundation organize Cities and Climate Action Workshop
04-Aug Biocon Biologics Announces Key Leadership Appointments
July-23
27-July Biocon Foundation Releases Second Edition of Consensus Guidelines for Head & Neck Cancer Marks the World Head & Neck Cancer Day at the OCTF Conference
24-July Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
05-July Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries
03-July After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States
June-23
30-June Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign
May-23
23-May Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
April-23
25-Apr Serum & Biocon Biologics Agree to Restructure Equity Investment
05-Apr Biocon Academy Conducted Graduation Ceremony For 185 Students across Four Programs
04-Apr Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments

FY 2022-23

March-23
28-Mar Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
February-23
14-Feb Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
January-23
24-Jan Biocon Foundation Wins the Prestigious ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022
December-22
22-Dec Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
14-Dec Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India
05-Dec Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Novermber-22
29-Nov Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
24-Nov Biocon Limited enters into a commercialization agreement with Zentiva in Europe
14-Nov Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
11-Nov Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
October-22
31-Oct Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine
17-Oct Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
07-Oct Biocon Foundation Receives ‘Mahatma Award 2022 for Excellence in Social Good’
September-22
24-Sep Kiran Mazumdar-Shaw Awarded with H.K. Firodia Lifetime Achievement Award 2022 for Excellence in Science & Technology
August-22
05-Aug Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
July-22
27-July Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%; Biosimilars Up 29%; Generics Up 19%; Research Services Up 8%
June-22
09-June University of Glasgow officially Opens Mazumdar Shaw Advance Research Centre
May-22
19-May Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
April-22
28-Apr Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9% Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr. FY22 Revenue at Rs 8,397 Cr, Up 14%; Core EBITDA Up 18% at Rs 2,669 Cr; PBT (before Exceptional Item) at Rs 1094 Cr, Up 4%
26-Apr Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
01-Apr Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion

FY 2021-22

March-22
29-Mar University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
23-Mar Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
February-22
27-Feb Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
January-22
20-Jan Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
December-21
30-Dec Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
23-Dec Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
07-Dec Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East
01-Dec Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
November-21
16-Nov Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
15-Nov Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
October-21
21-Oct Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
21-Oct Appointment of Dr. Eric Vivek Mazumdar as Non-Executive, Non-Independent Director of the Company
21-Oct Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
04-Oct Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US
September-21
16-Sep Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
July-21
29-July Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
26-July Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
22-July Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
April-21
29-Apr Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr. FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.
28-Apr Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award

FY 2020-21

Mar-21
29-Mar Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
02-Mar Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
01-Mar Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
01-Mar Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Feb-21
16-Feb Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
04-Feb Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia
Jan-21
21-Jan Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
21-Jan Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
07-Jan Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Dec-20
28-Dec Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
15-Dec Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Nov-20
07-Nov Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion
Oct-20
30-Oct Biocon Ranked Among Top 5 Biotech Employers Globally
22-Oct Press Release on financial results for the Quarter ended September 30, 2020
08-Oct Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Sep-20
22-Sep Biocon appoints Anupam Jindal as its Chief Financial Officer
Aug-20
31-Aug Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-Aug Disclosure of material impact of COVID 19 pandemic on the Company
03-Aug Execution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
Jul-20
31-Jul Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-Jul Press Release on financial results for the quarter ended June 30, 2020.
21-Jul Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-Jul Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Jun-20
22-Jun Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-Jun Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-Jun Kiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-Jun Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
May-20
27-May Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-May Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-May Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
Apr-20
28-Apr Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
14-Apr Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-Apr Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
ARCHIVES

FY: From April 1 – March 31

Know more
about us

>> Generics
>> Biocon Academy
>> Biocon Malaysia

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2023, Biocon. All Rights Reserved
Share